| 2.13 -0.17 (-7.39%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.28 | 1-year : | 3.91 |
| Resists | First : | 2.81 | Second : | 3.35 |
| Pivot price | 2.57 |
|||
| Supports | First : | 1.94 | Second : | 1.61 |
| MAs | MA(5) : | 2.19 |
MA(20) : | 2.68 |
| MA(100) : | 4.06 |
MA(250) : | 3.26  |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 21 |
D(3) : | 18.5 |
| RSI | RSI(14): 31.1 |
|||
| 52-week | High : | 7.75 | Low : | 1.39 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMMX ] has closed above bottom band by 12.1%. Bollinger Bands are 35.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.32 - 2.33 | 2.33 - 2.34 |
| Low: | 2.07 - 2.09 | 2.09 - 2.1 |
| Close: | 2.1 - 2.13 | 2.13 - 2.15 |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Thu, 18 Apr 2024
Immix Biopharma on Track to Dose NXC-201 Patients in United States - The Bakersfield Californian
Thu, 18 Apr 2024
Immix Biopharma on Track to Dose NXC-201 Patients in United States - GlobeNewswire
Mon, 15 Apr 2024
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th ... - GlobeNewswire
Tue, 05 Mar 2024
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative - Yahoo Finance
Wed, 21 Feb 2024
Immix Biopharma 12 Month Review Progress Update - Yahoo Finance
Wed, 07 Feb 2024
Immix Biopharma Announces New Offering, Sparks Investor Interest - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 45.9 (%) |
| Held by Institutions | 8.4 (%) |
| Shares Short | 389 (K) |
| Shares Short P.Month | 264 (K) |
| EPS | -0.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.81 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58 % |
| Return on Equity (ttm) | -106.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -2.4 |
| PEG Ratio | 0 |
| Price to Book value | 2.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|